Redeye is positive on Senzime’s recent news flow, with contracts from important US hospitals.
Redeye comments on Verve's announced acquisition. The company is acquiring Acardo Group for EUR24.
Redeye leaves a comment following OncoZenge’s announcement of a collaboration with UCLA, marking an ...
Redeye comments on the announcement that CEO Pål Ryfors will step down of his own volition, with cur...
Redeye is pleased with TO13’s preliminary subscription rate of 91%.
Grangex nya DFS för Sydvaranger ökar visibiliteten och pekar på ytterligare värden.
Redeye returns with minor estimate changes following a mixed report from Binero that faced higher OP...
Redeye comments on Cinclus’ announcement that the first patient has been screened in its pivotal Pha...
Redeye briefly comments on Guard announcing that the data collection for the phase IIb study POINTER...
Redeye leaves its Base Case unchanged following limited estimate revisions.
Redeye updates its view on Thunderful. Atari’s majority acquisition (80%) of Thunderful offers clear...
Biovica records SEK 2.6m in total net sales (51% above Q1 last year), and clinical sales increased b...
Redeye initiates coverage of Guard Therapeutics, a clinical-stage biotech developing innovative ther...
Smart Eye secures a milestone AIS order from fleet safety provider Optix, marking the first large-sc...
Redeye return with a research update following BioArctic's Q2 and latest newsflow.
